ROMEG Therapeutics Secures Two Additional U.S. Patents

WOBURN, Mass. (Aug. 20, 2019) – ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued two additional U.S. patents that are directed to the formulation, methods of use and ...

Read More

Avion Pharmaceuticals, LLC and ROMEG Therapeutics, LLC finalize partnership agreement to license and commercialize Gloperba, a prophylactic treatment of gout in adults

ATLANTA, (July 16, 2019) – Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, has announced the license and commercialization agreement with ROMEG Therapeutics, LLC, for the exclusive rights to launch Gloperba – an oral solution for adults suffering from gout – in the United States. Gloperba is a new liquid oral ...

Read More

FDA Approval for GLOPERBA

ROMEG has received FDA approval for its product GLOPERBA®.   FOR IMMEDIATE RELEASE Contact: Greg Turner, Ball Consulting Group, LLC Phone: 617-243-9950 Email: greg@ballcg.com   ROMEG Therapeutics Receives FDA Approval of GLOPERBA® (colchicine) for Prophylaxis of Adult Gout Flares GLOPERBA® is the First FDA-approved Liquid Formulation for Prophylaxis of Gout Flares ...

Read More